person · Reporting owner

Barbarosh Craig A.

Disclosed activity across 7 companies

Tapewire entity: 911
SEC CIK: 0001472457

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bazaarvoice IncBV · Entity 169747	Director	February 01, 2018	February 05, 2018
Evolent Health, Inc.EVH · Entity 5492	Director	June 04, 2026	June 08, 2026
LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447	Director	July 08, 2024	July 10, 2024
ModivCare IncMODV · Entity 76927	Director	December 23, 2024	January 03, 2025
NEXTGEN HEALTHCARE, INC.NXGN · Entity 108396	Director	November 09, 2023	November 13, 2023
Sabra Health Care REIT, Inc.SBRA · Entity 886	Director	August 31, 2026	September 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bazaarvoice Inc

Report date February 01, 2018 · Filed February 05, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2018-02-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-02-01 · Disposition to issuer · Disposed 1,720 · Balance 18,920 F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among BV Parent, LLC, BV Merger Sub, Inc. and Bazaarvoice, Inc. (the "Issuer"), dated November 26, 2017 (as amended, the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $5.50 per share. Row 2 · 2018-02-01 · Disposition to issuer · Disposed 18,920 · Balance 0 F2: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock were cancelled in exchange for cash payments in the amount of $5.50 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among BV Parent, LLC, BV Merger Sub, Inc. and Bazaarvoice, Inc. (the "Issuer"), dated November 26, 2017 (as amended, the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $5.50 per share.

F2: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock were cancelled in exchange for cash payments in the amount of $5.50 per share.

Evolent Health, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	95,031	Reported balance After 2026-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 41,096 · Balance 95,031 F1: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2: Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2: Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.

LIFECORE BIOMEDICAL, INC. \DE\

Report date July 08, 2024 · Filed July 10, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectIn Trust	88,073	Reported balance After 2024-07-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-07-08 · Grant · Acquired 30,000 · Balance 88,073 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

ModivCare Inc

Report date December 23, 2024 · Filed January 03, 2025

This filing explicitly reported no securities owned.

NEXTGEN HEALTHCARE, INC.

Report date November 09, 2023 · Filed November 13, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance After 2023-11-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-11-09 · Disposition to issuer · Disposed 67,269 · Balance 0 F1: Includes 10,086 outstanding vested shares of restricted stock. F2: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had F3: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level. F4: The ownership form includes both direct and indirect holdings. F5: Indirect ownership includes the holdings of the The Barbarosh Family Trust established May 29, 2007.
Deferred Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-11-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-11-09 · Disposition to issuer · Disposed 9,483 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had F3: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level. F6: The Deferred Stock Units credited under the Deferred Compensation Plan are generally payable in the form elected or provided under the Deferred Compensation Plan on the earlier of (i) the date or event elected by the reporting person, (ii) within 90 days following the participant's separation from service as defined under the Deferred Compensation Plan, or (ii) upon death, disability or change in control as defined under the Deferred Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 10,086 outstanding vested shares of restricted stock.

F2: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had

F3: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level.

F4: The ownership form includes both direct and indirect holdings.

F5: Indirect ownership includes the holdings of the The Barbarosh Family Trust established May 29, 2007.

F6: The Deferred Stock Units credited under the Deferred Compensation Plan are generally payable in the form elected or provided under the Deferred Compensation Plan on the earlier of (i) the date or event elected by the reporting person, (ii) within 90 days following the participant's separation from service as defined under the Deferred Compensation Plan, or (ii) upon death, disability or change in control as defined under the Deferred Compensation Plan.

Sabra Health Care REIT, Inc.

Report date August 31, 2026 · Filed September 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	54,580	Reported balance After 2026-08-31 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-08-31 · Grant · Acquired 791 · Balance 54,580 F1: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2: Consists of 7,027 unvested stock units and 47,553 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock.
Common StockSEC Table I · non-derivative	IndirectBy The Barbarosh Family Trust	104,453	Reported balance Holding disclosure · report date 2026-08-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 104,453

Filing footnotes · ownership attribution and instrument terms

F1: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate.

F2: Consists of 7,027 unvested stock units and 47,553 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARATANA THERAPEUTICS, INC.

Report date July 18, 2019 · Filed July 18, 2019

Section 16 reporting ended · disclosed 2019-07-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-07-18 transaction · row 1 1 source row Row 1 · 2019-07-18 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.34	Direct	Reported balance After 2019-07-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-07-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80	Direct	Reported balance After 2019-07-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.

Filing footnotes · ownership attribution and instrument terms

F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2)

F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration").

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards.

F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 30, 2021 Filed Dec 2, 2021 21:42 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	785	$0.00	$0.00	Disclosure SEC source: 0001862128-21-000094 · wf-form4_163848133252438.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,882 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 3,916 unvested stock units and 43,966 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
November 02, 2021 Filed Nov 4, 2021 16:57 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	GrantCommon Stock	14,237	$0.00	$0.00	Disclosure SEC source: 0001209191-21-062955 · doc4.xml · nonDerivative · entry 2 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,183 Read SEC document
November 02, 2021 Filed Nov 4, 2021 16:57 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	SaleCommon Stock	9,000	$16.54	$148,865.40	Disclosure SEC source: 0001209191-21-062955 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,946 F1 · kind: Pursuant to a 10b5-1(c) plan adopted by the reporting person on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.345 to $16.69. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request. Read SEC document
August 31, 2021 Filed Sep 2, 2021 20:19 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	624	$0.00	$0.00	Disclosure SEC source: 0001862128-21-000068 · wf-form4_163061396788383.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,792 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 5,465 unvested stock units and 42,327 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 03, 2021 Filed Aug 3, 2021 21:01 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	SaleCommon Stock	9,000	$16.14	$145,224.00	Disclosure SEC source: 0001209191-21-049507 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,946 F1 · kind: Pursuant to a 10b5-1(c) plan adopted by the reporting person on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.87 to $16.27. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request. Read SEC document
June 16, 2021 Filed Jun 17, 2021 18:49 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	6,438	$0.00	$0.00	Disclosure SEC source: 0001862128-21-000041 · wf-form4_162395578576559.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,015 F1 · shares: Grant of restricted stock units under the Issuer's 2009 Performance Incentive Plan. The units vest in equal monthly installments beginning July 16, 2021 and ending on the earlier of June 15, 2022 or the day before the date of the next annual stockholders' meeting. F2 · balance_after: Consists of 6,438 unvested stock units and 41,577 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 10, 2021 Filed Jun 14, 2021 21:46 UTC	Evolent Health, Inc. EVH · Entity 5492	GrantClass A Common Stock	7,785	$0.00	$0.00	Disclosure SEC source: 0001628908-21-000082 · wf-form4_162370720309393.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,634 F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 10, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document
June 04, 2021 Filed Jun 8, 2021 23:58 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRestricted Stock Unit · Derivative	7,059	Not disclosed	Not disclosed	Disclosure SEC source: 0001593968-21-001569 · primary_01.xml · derivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,059 Underlying: Common Stock · 7,059 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
June 01, 2021 Filed Jun 2, 2021 16:06 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	SaleCommon Stock	9,000	$16.56	$149,065.20	Disclosure SEC source: 0001209191-21-037124 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,946 F1 · kind: Pursuant to a 10b5-1(c) plan adopted by the reporting person on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.145 to $16.76. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request. Read SEC document
June 01, 2021 Filed Jun 4, 2021 00:08 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	8,303	$11.64	$96,646.92	Disclosure SEC source: 0001593968-21-001525 · primary_01.xml · derivative · entry 2 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,303 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on June 1, 2020. F3 · derivative.exercise_date: The restricted stock units vested on June 1, 2021. F3 · derivative.expiration_date: The restricted stock units vested on June 1, 2021. Read SEC document
June 01, 2021 Filed Jun 4, 2021 00:08 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	8,303	$11.64	$96,646.92	Disclosure SEC source: 0001593968-21-001525 · primary_01.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 13,804 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
May 28, 2021 Filed Jun 2, 2021 18:14 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	454	$0.00	$0.00	Disclosure SEC source: 0001862128-21-000021 · wf-form4_162265766183631.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,577 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 633 unvested stock units and 40,944 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
April 12, 2021 Filed Apr 13, 2021 16:29 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	SaleCommon Stock	9,000	$18.70	$168,342.30	Disclosure SEC source: 0001209191-21-026440 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,946 F1 · kind: Pursuant to a 10b5-1(c) plan adopted by the reporting person on March 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.58 to $18.8450. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its stockholders upon request. Read SEC document
February 26, 2021 Filed Mar 3, 2021 00:55 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	452	$0.00	$0.00	Disclosure SEC source: 0001510192-21-000039 · wf-form4_161473293584409.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,994 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 2,487 unvested stock units and 39,507 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:56 UTC	Evolent Health, Inc. EVH · Entity 5492	GrantClass A Common Stock	3,849	$0.00	$0.00	Disclosure SEC source: 0001628908-21-000002 · wf-form4_160997736594444.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,849 F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of January 4, 2022 and the date of the Company's 2021 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document
November 30, 2020 Filed Dec 3, 2020 00:37 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	464	$0.00	$0.00	Disclosure SEC source: 0001510192-20-000127 · wf-form4_160695586189185.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,407 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 4,276 unvested stock units and 38,131 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:13 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	Exercise / conversionRestricted Stock Unit · Derivative	5,501	$0.00	$0.00	Disclosure SEC source: 0001593968-20-002067 · primary_01.xml · derivative · entry 2 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,501 shares Expires 2020-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on October 15, 2019. F3 · derivative.exercise_date: The restricted stock units vested on October 15, 2020. F3 · derivative.expiration_date: The restricted stock units vested on October 15, 2020. Read SEC document
October 15, 2020 Filed Oct 19, 2020 20:13 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantCommon Stock	5,501	$10.36	$56,990.36	Disclosure SEC source: 0001593968-20-002067 · primary_01.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 5,501 F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document
August 31, 2020 Filed Sep 2, 2020 22:46 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	505	$0.00	$0.00	Disclosure SEC source: 0001510192-20-000106 · wf-form4_159908676225262.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,697 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 5,999 unvested stock units and 36,698 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 18, 2020 Filed Aug 19, 2020 16:30 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	GrantCommon Stock	14,706	$0.00	$0.00	Disclosure SEC source: 0001209191-20-047496 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,946 Read SEC document
June 09, 2020 Filed Jun 12, 2020 01:40 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	7,055	$0.00	$0.00	Disclosure SEC source: 0001510192-20-000084 · wf-form4_159192601337870.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,830 F1 · shares: Grant of restricted stock units under the Issuer's 2009 Performance Incentive Plan. The units vest in equal monthly installments beginning July 9, 2020 and ending on the earlier of June 8, 2020 or the day before the date of the next annual stockholders' meeting. F2 · balance_after: Consists of 7,055 unvested stock units and 35,775 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 01, 2020 Filed Jun 2, 2020 22:30 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRight to Buy Restricted Stock Unit (RSU) · Derivative	8,303	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-20-008856 · wf-form4_159113700128431.xml · derivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,303 Underlying: Common Stock · 8,303 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
May 29, 2020 Filed Jun 2, 2020 20:33 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	390	$0.00	$0.00	Disclosure SEC source: 0001510192-20-000068 · wf-form4_159113000153784.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,775 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 532 unvested stock units and 35,243 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 28, 2020 Filed Mar 4, 2020 00:29 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	395	$0.00	$0.00	Disclosure SEC source: 0001510192-20-000038 · wf-form4_158328174842252.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,875 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 2,085 unvested stock units and 33,790 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
December 31, 2019 Filed Jan 2, 2020 23:18 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,171	$0.00	$0.00	Disclosure SEC source: 0001510192-20-000003 · wf-form4_157800709136826.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,480 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or December 31, 2024. F2 · balance_after: Consists of 3,058 unvested stock units and 32,422 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
November 29, 2019 Filed Dec 4, 2019 00:27 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	339	$0.00	$0.00	Disclosure SEC source: 0001510192-19-000144 · wf-form4_157541923010582.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,844 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 3,568 unvested stock units and 31,276 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
October 15, 2019 Filed Oct 17, 2019 19:14 UTC	LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447	GrantRight to Buy Restricted Stock Unit (RSU) · Derivative	5,501	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-19-012369 · wf-form4_157133961156225.xml · derivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,501 Underlying: Common Stock · 5,501 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document
September 30, 2019 Filed Oct 1, 2019 21:41 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,088	$0.00	$0.00	Disclosure SEC source: 0001510192-19-000126 · wf-form4_156996606381150.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,505 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or September 30, 2024. F2 · balance_after: Consists of 4,497 unvested stock units and 30,008 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 30, 2019 Filed Sep 4, 2019 22:07 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	343	$0.00	$0.00	Disclosure SEC source: 0001510192-19-000114 · wf-form4_156763485883520.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,085 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Consists of 4,998 unvested stock units and 29,087 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 15, 2019 Filed Aug 16, 2019 17:49 UTC	NEXTGEN HEALTHCARE, INC. NXGN · Entity 108396	GrantCommon Stock	14,187	$0.00	$0.00	Disclosure SEC source: 0001209191-19-046385 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 85,240 F1 · ownership.nature: The Barbarosh Family Trust established May 29, 2007 Read SEC document
July 18, 2019 Filed Jul 18, 2019 23:40 UTC	ARATANA THERAPEUTICS, INC. PETX · Entity 155913	Disposition to issuerStock Option (Right to Buy) · Derivative	7,500	Not disclosed Strike: $4.80	Not disclosed	Disclosure SEC source: 0001209191-19-042716 · doc4.xml · derivative · entry 3 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document
July 18, 2019 Filed Jul 18, 2019 23:40 UTC	ARATANA THERAPEUTICS, INC. PETX · Entity 155913	Disposition to issuerStock Option (Right to Buy) · Derivative	30,000	Not disclosed Strike: $5.34	Not disclosed	Disclosure SEC source: 0001209191-19-042716 · doc4.xml · derivative · entry 2 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares. Read SEC document
July 18, 2019 Filed Jul 18, 2019 23:40 UTC	ARATANA THERAPEUTICS, INC. PETX · Entity 155913	Disposition to issuerCommon Stock	4,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-042716 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2 · shares: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3 · shares: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards. F1 · price: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2 · price: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). Read SEC document
June 28, 2019 Filed Jul 4, 2019 01:37 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,269	$0.00	$0.00	Disclosure SEC source: 0001510192-19-000092 · wf-form4_156220426465393.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,742 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or June 28, 2024. F2 · balance_after: Consists of 5,876 unvested stock units and 27,866 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 21, 2019 Filed Jun 25, 2019 18:19 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	5,876	$0.00	$0.00	Disclosure SEC source: 0001510192-19-000075 · wf-form4_156148676589419.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,018 F1 · shares: Grant of restricted stock units under the Issuer's 2009 Performance Incentive Plan. The units vest in equal monthly installments beginning July 21, 2019 and ending on the earlier of June 20, 2020 or the day before the date of the next annual stockholders' meeting. F2 · balance_after: Consists of 5,876 unvested stock units and 27,142 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 06, 2019 Filed Jun 7, 2019 21:47 UTC	ARATANA THERAPEUTICS, INC. PETX · Entity 155913	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $4.80	$0.00	Disclosure SEC source: 0001209191-19-035627 · doc4.xml · derivative · entry 2 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-05 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document
June 06, 2019 Filed Jun 7, 2019 21:47 UTC	ARATANA THERAPEUTICS, INC. PETX · Entity 155913	GrantCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0001209191-19-035627 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document
May 31, 2019 Filed Jun 4, 2019 23:18 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	240	$0.00	$0.00	Disclosure SEC source: 0001510192-19-000067 · wf-form4_155969027776924.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,266 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 446 unvested stock units and 26,696 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
March 29, 2019 Filed Apr 1, 2019 21:20 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,284	$0.00	$0.00	Disclosure SEC source: 0001510192-19-000048 · wf-form4_155415359544475.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,026 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or March 29, 2024. F2 · balance_after: Includes 1,310 unvested stock units and 25,592 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 28, 2019 Filed Mar 5, 2019 02:49 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	252	$0.00	$0.00	Disclosure SEC source: 0001510192-19-000031 · wf-form4_155175414922869.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,742 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 1,749 unvested stock units and 24,429 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
December 31, 2018 Filed Jan 4, 2019 01:46 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,213	$0.00	$0.00	Disclosure SEC source: 0001510192-19-000009 · wf-form4_154656634379495.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,490 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or December 31, 2023. F2 · balance_after: Includes 2,562 unvested stock units and 23,364 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
November 30, 2018 Filed Dec 4, 2018 18:21 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	230	$0.00	$0.00	Disclosure SEC source: 0001510192-18-000128 · wf-form4_154394766946613.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,277 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 2,990 unvested stock units and 22,320 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
September 28, 2018 Filed Oct 2, 2018 16:33 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	865	$0.00	$0.00	Disclosure SEC source: 0001510192-18-000113 · wf-form4_153849798903472.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,047 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or September 28, 2023. F2 · balance_after: Includes 3,758 unvested stock units and 21,322 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 31, 2018 Filed Sep 5, 2018 22:21 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	184	$0.00	$0.00	Disclosure SEC source: 0001510192-18-000100 · wf-form4_153618608580225.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,182 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 4,176 unvested stock units and 20,718 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
August 14, 2018 Filed Aug 15, 2018 16:57 UTC	NEXTGEN HEALTHCARE, INC. QSII · Entity 108396	GrantCommon Stock	8,460	$0.00	$0.00	Disclosure SEC source: 0001209191-18-046841 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 71,053 F1 · ownership.nature: The Barbarosh Family Trust established May 29, 2007 Read SEC document
June 29, 2018 Filed Jul 3, 2018 21:29 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	920	$0.00	$0.00	Disclosure SEC source: 0001510192-18-000086 · wf-form4_153065337862610.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,998 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or June 29, 2023. F2 · balance_after: Includes 4,918 unvested stock units and 19,792 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 21, 2018 Filed Jun 21, 2018 23:41 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	4,918	$0.00	$0.00	Disclosure SEC source: 0001510192-18-000077 · wf-form4_152962448318883.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,078 F1 · shares: Grant of restricted stock units under the Issuer's 2009 Performance Incentive Plan. The units vest in equal monthly installments beginning July 21, 2018 and ending on the earlier of June 20, 2019 or the day before the date of the next annual stockholders' meeting. F2 · balance_after: Includes 4,918 unvested stock units and 19,470 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
May 31, 2018 Filed Jun 5, 2018 01:57 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	101	$0.00	$0.00	Disclosure SEC source: 0001510192-18-000061 · wf-form4_152816385585397.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,160 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 395 unvested stock units and 19,075 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
May 18, 2018 Filed May 22, 2018 21:37 UTC	ARATANA THERAPEUTICS, INC. PETX · Entity 155913	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $5.34	$0.00	Disclosure SEC source: 0001209191-18-032373 · doc4.xml · derivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: Vests in four equal installments on each of the first four anniversaries of the grant date, subject to continued service to the Issuer through the applicable vesting dates. Read SEC document
March 30, 2018 Filed Apr 3, 2018 13:31 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,133	$0.00	$0.00	Disclosure SEC source: 0001510192-18-000049 · wf-form4_152276225566017.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,059 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or March 30, 2023. F2 · balance_after: Includes 1,163 unvested stock units and 18,206 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.